These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 38609993)

  • 1. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
    Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
    Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.
    Sohn MH; Kim SI; Shin JY; Kim HS; Chung HH; Kim JW; Lee M; Seo JS
    Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
    Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic Mutational Profile of High-Grade Serous Ovarian Carcinoma and Triple-Negative Breast Carcinoma in Young and Elderly Patients: Similarities and Divergences.
    Serio PAMP; de Lima Pereira GF; Katayama MLH; Roela RA; Maistro S; Folgueira MAAK
    Cells; 2021 Dec; 10(12):. PubMed ID: 34944094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinome capture sequencing of high-grade serous ovarian carcinoma reveals novel mutations in the JAK3 gene.
    Mittempergher L; Piskorz AM; Bosma AJ; Michaut M; Wisman GBA; Kluin RJC; Nieuwland M; Brugman W; van der Ven KJW; Marass F; Morris J; Rosenfeld N; Jimenez-Linan M; de Jong S; van der Zee AGJ; Brenton JD; Bernards R
    PLoS One; 2020; 15(7):e0235766. PubMed ID: 32639993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.
    Weberpals JI; Pugh TJ; Marco-Casanova P; Goss GD; Andrews Wright N; Rath P; Torchia J; Fortuna A; Jones GN; Roudier MP; Bernard L; Lo B; Torti D; Leon A; Marsh K; Hodgson D; Duciaume M; Howat WJ; Lukashchuk N; Lazic SE; Whelan D; Sekhon HS
    Cancer Med; 2021 May; 10(9):3045-3058. PubMed ID: 33811746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Somatic
    Garziera M; Cecchin E; Canzonieri V; Sorio R; Giorda G; Scalone S; De Mattia E; Roncato R; Gagno S; Poletto E; Romanato L; Sartor F; Polesel J; Toffoli G
    Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29783665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomic characterization of Chinese ovarian clear cell carcinoma identifies driver genes by whole exome sequencing.
    Yang Q; Zhang C; Ren Y; Yi H; Luo T; Xing F; Bai X; Cui L; Zhu L; Ouyang J; Jiang P; Fan W; Qiu J; Wang F; Xing X; Zhang Z; Zhang X; Zhang R
    Neoplasia; 2020 Sep; 22(9):399-430. PubMed ID: 32650224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.
    Filippova OT; Selenica P; Pareja F; Vahdatinia M; Zhu Y; Pei X; Riaz N; Long Roche K; Chi DS; Abu-Rustum NR; Ellenson LH; Reis-Filho JS; Zamarin D; Weigelt B
    Gynecol Oncol; 2021 May; 161(2):545-552. PubMed ID: 33674143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
    Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
    PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
    Zhang P; He M; Zeng Y; Cai X
    Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients.
    Buttarelli M; Ciucci A; Palluzzi F; Raspaglio G; Marchetti C; Perrone E; Minucci A; Giacò L; Fagotti A; Scambia G; Gallo D
    J Exp Clin Cancer Res; 2022 Feb; 41(1):50. PubMed ID: 35120576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases.
    Masoodi T; Siraj S; Siraj AK; Azam S; Qadri Z; Parvathareddy SK; Tulbah A; Al-Dayel F; AlHusaini H; AlOmar O; Al-Badawi IA; Alkuraya FS; Al-Kuraya KS
    Br J Cancer; 2020 Apr; 122(8):1219-1230. PubMed ID: 32099096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.
    Xu Y; Zhang Q; Miao C; Dongol S; Li Y; Jin C; Dong R; Li Y; Yang X; Kong B
    Cancer Med; 2019 Jan; 8(1):351-362. PubMed ID: 30565428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.
    Cheasley D; Nigam A; Zethoven M; Hunter S; Etemadmoghadam D; Semple T; Allan P; Carey MS; Fernandez ML; Dawson A; Köbel M; Huntsman DG; Le Page C; Mes-Masson AM; Provencher D; Hacker N; Gao Y; Bowtell D; deFazio A; Gorringe KL; Campbell IG
    J Pathol; 2021 Jan; 253(1):41-54. PubMed ID: 32901952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
    Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
    Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer.
    Raab M; Kostova I; Peña-Llopis S; Fietz D; Kressin M; Aberoumandi SM; Ullrich E; Becker S; Sanhaji M; Strebhardt K
    Cancer Commun (Lond); 2024 Jan; 44(1):101-126. PubMed ID: 38140698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paired comparison of the analytical performance between the Oncomine™ Comprehensive Assay v3 and whole-exome sequencing of ovarian cancer tissue.
    Lopacinska-Jørgensen J; Vestergaard LK; Schejbel L; Høgdall CK; Poulsen TS; Høgdall EV
    Mol Biol Rep; 2024 Jul; 51(1):820. PubMed ID: 39017860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Kim SI; Lee JW; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
    Gynecol Oncol; 2018 Feb; 148(2):375-382. PubMed ID: 29233531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.